Abstract 2373P
Background
The phase 3 KEYNOTE-361 trial (NCT02853305) of 1L pembrolizumab + chemotherapy (chemo) or pembrolizumab vs chemo alone in pts with advanced UC completed enrollment prior to approval of PD-L1 maintenance therapy after 1L chemo. This post hoc exploratory analysis evaluated pts who received chemo by eligibility for post-chemo maintenance therapy.
Methods
Pts who received chemo alone were retrospectively categorized as eligible (received ≥4 cycles of chemo and either did not have PD or died within 0-10 wk after completion of chemo or did have a PD or died >10 wk after completion of chemo) or ineligible (received ≥4 cycles of chemo and had a PD or died while on chemo or within 0-10 wk after completion of chemo) for post-chemo maintenance. Pts who received <4 cycles of chemo, were censored before end of chemo, or had nonevaluable or missing scans within 10 wk of chemo were excluded. Exploratory end points were PFS, landmark PFS (time from last non-PD assessment within 0-10 wk of chemo completion to PD per RECIST v1.1 by BICR), OS, and landmark OS (time from last non-PD assessment within 0-10 wk of chemo completion to death).
Results
Median follow-up was 31.7 mo (range, 22.0-42.3). Among 342 pts in the chemo arm, 172 (50.3%) were eligible for maintenance, 108 (31.6%) were ineligible, and 62 (18.1%) were excluded; 85/172 pts (49.4%) received subsequent anti–PD-1/L1 therapy. Results for pts eligible for post-chemo maintenance are reported (Table). For maintenance-ineligible pts, median (95% CI) PFS and OS were 5.1 mo (4.2-6.0) and 10.2 mo (9.1-11.6), respectively.
Conclusions
This post hoc exploratory analysis demonstrates that pts who are eligible for post-chemo maintenance therapy have a favorable prognosis. About 50% of pts who initiated chemo on a clinical trial were considered eligible for maintenance therapy. To our knowledge, these are the first exploratory data describing outcomes of maintenance-eligible pts from the initiation of chemo. Table: 2373P
Maintenance eligible n = 172 | |
PFS, median (95% CI%), mo | 9.0 (8.4-10.4) |
PFS rate at 12 mo, % (95% CI) | 35.1 (27.3-43.0) |
Landmark PFS, median (95% CI), mo | 4.1 (2.9-6.1) |
Landmark PFS rate at 12 mo, % (95% CI) | 25.2 (17.9-33.2) |
OS, median (95% CI, mo) | 23.3 (19.4-26.1) |
OS rate at 24 mo, % (95% CI) | 46.8 (39.2-54.1) |
Landmark OS, median (95% CI), mo | 18.8 (14.6-21.8) |
Landmark OS rate at 24 mo, % (95% CI) | 39.9 (32.2-47.5) |
Clinical trial identification
NCT02853305; Release date: August 2, 2016.
Editorial acknowledgement
Medical writing and/or editorial assistance was provided by Matthew Grzywacz, PhD of ApotheCom (Yardley, PA, USA).
Legal entity responsible for the study
Merck Sharp & Dohme Llc, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Funding
Merck Sharp & Dohme Llc, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Disclosure
R. Mamtani: Non-Financial Interests, Institutional, Research Grant: Merck, Astellas; Non-Financial Interests, Personal, Advisory Board: Seagen, BMS. N. Matsubara: Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Other, Consultancy (including expert testimony): Janssen, MSD, Eli Lilly; Financial Interests, Institutional, Research Grant: Janssen, AstraZeneca, Bayer, MSD, Taiho, Astellas, Amgen, Eisai, Eli Lilly, Takeda, Pfizer, Seagen, Chugai, AbbVie, Novartis. A. Montesa Pino: Financial Interests, Personal, Advisory Board: Pfizer, Merck, Astellas, MSD, AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: Pfizer, Merck, Astellas, MSD, AstraZeneca. M.A.N. Sendur: Financial Interests, Personal, Invited Speaker: Astellas, Roche, Takeda, Pfizer, Novartis, Bayer; Financial Interests, Personal, Advisory Board: Astellas, Roche, Takeda, Pfizer, Novartis, Bayer, BMS. U. Anido Herranz: Financial Interests, Personal, Invited Speaker: Advanced Accelerator Applications, Ipsen, AstraZeneca, Merck, Pfizer, Astellas, Bayer, Eisai, BMS, Kyowa Kirin, Rovi; Financial Interests, Personal, Advisory Board: Advanced Accelerator Applications, Ipsen, AstraZeneca, Merck, Pfizer, Bayer. G. Gravis: Financial Interests, Institutional, Invited Speaker: AAA, Amgen, Astellas, BMS, Janssen, MSD, Pfizer, Ipsen, AstraZeneca, Alliance Merck-Pfizer, Bayer, Eisai; Financial Interests, Institutional, Advisory Board: Alliance Merck-Pfizer, BMS, Janssen, Pfizer, Ipsen, Bayer, Eisai; Financial Interests, Institutional, Funding: Janssen; Financial Interests, Institutional, Coordinating PI: BMS; Non-Financial Interests, Principal Investigator: Ipsen, BMS, Merck. O. Huillard: Financial Interests, Personal, Invited Speaker: Sanofi, Ipsen, Novartis; Financial Interests, Personal, Advisory Board: Janssen, Bristol Myers Squibb, AstraZeneca, Pfizer, Eisai, Bayer, AAA. R. Gafanov: Financial Interests, Personal, Speaker’s Bureau: Janssen, Astellas, Roche, Ipsen, Eisai, Pfizer, Merck, AstraZeneca, MSD; Financial Interests, Personal, Advisory Board: Janssen, Astellas, Roche, Ipsen, Eisai, Pfizer, Merck, AstraZeneca, MSD; Financial Interests, Personal, Research Grant: Janssen, Astellas, Roche, AstraZeneca, MSD. F. Joly Lobbedez: Financial Interests, Personal, Advisory Board: GSK, AstraZeneca, MSD, Janssen, Ipsen, BMS, Bayer, Eisai; Financial Interests, Personal, Invited Speaker: GSK, AstraZeneca, MSD, Janssen, Ipsen, Amgen, Astellas; Financial Interests, Institutional, Coordinating PI: GSK, AstraZeneca; Financial Interests, Institutional, Research Grant: BMS; Other, travel: MSD, GSK. J. Bedke: Financial Interests, Personal, Advisory Board: AstraZeneca, Astellas, Eisai; Financial Interests, Personal, Advisory Board, Advisory Board and Speaker´s Bureau: BMS, Ipsen, MSD, Merck Serono, Pfizer, Roche, Janssen; Financial Interests, Institutional, Advisory Board: BMS, Pfizer; Financial Interests, Institutional, Local PI: AstraZeneca, Eisai, Novartis, Nektar; Financial Interests, Institutional, Coordinating PI: Astellas, BMS, MSD, Ipsen, Pfizer, Roche, Seagen; Financial Interests, Institutional, Steering Committee Member: BMS, MSD, Pfizer, Seagen; Other, Member of the Renal Cell Carcinoma Guidelines Panel: European Association of Urology. A. Sella: Financial Interests, Personal and Institutional, Advisory Board: Shamir, Asaf Harofe Medical Center; Financial Interests, Personal and Institutional, Invited Speaker: Shamir, Asaf Harofe Medical Center; Financial Interests, Personal and Institutional, Research Grant: Shamir, Asaf Harofe Medical Center. K. Imai: Financial Interests, Personal, Full or part-time Employment: Merck & Co Inc; Financial Interests, Personal, Stocks/Shares: Merck & Co Inc. B. Homet Moreno: Financial Interests, Institutional, Stocks/Shares: Merck; Financial Interests, Institutional, Full or part-time Employment: Merck. J. Xu: Financial Interests, Institutional, Stocks or ownership: Merck; Financial Interests, Institutional, Full or part-time Employment: Merck. A. Alva: Financial Interests, Personal, Advisory Role: AstraZeneca, Merck, Pfizer, BMS; Financial Interests, Institutional, Research Funding: Genentech, Bristol Myers Squibb, Merck Sharp & Dohme, Prometheus Laboratories, Mirati Therapeutics, AstraZeneca, Roche, Bayer, Astellas Pharma, Arcus Biosciences, Progenics, Celgene, Janssen; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Merck, BMS. T.B. Powles: Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol Myers Squibb, Exelixis, Incyte, Ipsen, Merck, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, Roche, MSD; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Roche, Pfizer, MSD, AstraZeneca, Ipsen; Financial Interests, Personal, Other, Sponsorship for Uromigos Podcast: Mashup Ltd; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Bristol Myers Squibb, Exelixis, Ipsen, Merck, MSD, Seattle Genetics, Novartis, Pfizer, Merck Serono, Astellas, Johnson & Johnson, Eisai. All other authors have declared no conflicts of interest.
Resources from the same session
1911P - Effect of VHL mutations on efficacy of immune checkpoint inhibitors in renal cell carcinoma
Presenter: Guojie Yu
Session: Poster session 23
1912TiP - STELLAR-304: A randomized phase III study of zanzalintinib (XL092) and nivolumab in non-clear cell renal cell carcinoma (nccRCC)
Presenter: Sumanta Pal
Session: Poster session 23
2366P - Phase I-II study of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial)
Presenter: Daniel Castellano Gauna
Session: Poster session 23
2367P - A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Russells Pachynski
Session: Poster session 23
2368P - Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
Presenter: Patrizia Giannatempo
Session: Poster session 23
2369P - Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)
Presenter: Bradley McGregor
Session: Poster session 23
2370P - Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Achille Bottiglieri
Session: Poster session 23
2371P - Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
Presenter: Shilpa Gupta
Session: Poster session 23
2372P - Efficacy of a tailored approach with nivolumab (N) and nivolumab+ipilimumab (N+I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC
Presenter: Marc-Oliver Grimm
Session: Poster session 23
2374P - A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
Presenter: Petros Grivas
Session: Poster session 23